ArticlePrzeglad menopauzalny = Menopause review2025
Burden of steatotic liver disease in postmenopausal women: NHANES 2017-2020 insights.
Article in Przeglad menopauzalny = Menopause review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The term steatotic liver disease (SLD) has replaced fatty liver disease following the Delphi consensus process. Recent trends indicate an increasing prevalence of SLD among women, particularly postmenopausal women. This study evaluates the prevalence of SLD in pre- and postmenopausal women and identifies risk factors contributing to its development. Material and methods: We conducted a cross-sectional analysis using data from the National Health and Nutrition Examination Survey (NHANES) 2017-2020. Adults aged ≥18 years with available controlled attenuation parameter (CAP) and liver stiffness measures (LSM) from vibration-controlled transient elastography were included. SLD and its subtypes - metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic-alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD) - were classified according to the consensus definitions. Menopausal status was determined via self-reported reproductive health data. Multivariate logistic regression identified risk factors for SLD and liver fibrosis, adjusting for demographic and metabolic variables. Results: Steatotic liver disease prevalence was significantly higher in postmenopausal women (34.57% vs. 23.49%, Conclusions: Postmenopausal women face an increased burden of SLD, likely due to metabolic risk factors and estrogen loss. Preventive interventions are needed to reduce SLD-related morbidity in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.